Cyramza is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: As a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ... Read more Cyramza is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: As a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. In combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. In combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Cyramza. In combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. As a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha-fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
For intravenous infusion only. Do not administer as an intravenous push or bolus. Premedicate before each infusion. Gastric Cancer : Administer Ramucirumab 8 mg/kg every 2 weeks as a single agent or in combination with weekly paclitaxel. Non-Small Cell Lung Cancer : Administer Ramucirumab 10 mg/kg every 2 weeks with daily erlotinib. Administer Ramucirumab 10 mg/kg on Day 1 of a 21-day cycle prior to docetaxel. Colorectal Cancer : Administer Ramucirumab 8 mg/kg every 2 weeks prior to FOLFIRI. Hepatocellular Carcinoma : Administer Ramucirumab 8 mg/kg every 2 weeks.
The most common adverse reactions observed in single agent Cyramza-treated gastric cancer patients at a rate of ≥10% and ≥2% higher than placebo were hypertension and diarrhea. The most common adverse reactions observed in patients treated with Cyramza with paclitaxel at a rate of ≥30% and ≥2% higher than placebo with paclitaxel were fatigue/asthenia, neutropenia, diarrhea, and epistaxis. The most common adverse reactions observed in patients treated with Cyramza with erlotinib at a rate of ≥30% and ≥2% higher than placebo with erlotinib were, infections, hypertension, stomatitis, proteinuria, alopecia, and epistaxis. The most common laboratory abnormalities at a rate of ≥30% and ≥2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anemia, thrombocytopenia, and neutropenia. The most common adverse reactions observed in patients treated with Cyramza with docetaxel at a rate of ≥30% and ≥2% higher than placebo with docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation. The most common adverse reactions observed in patients treated with Cyramza with FOLFIRI at a rate of ≥30% and ≥2% higher than placebo with FOLFIRI were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis. The most common adverse reactions observed in single agent Cyramza-treated HCC patients at a rate of ≥15% and ≥2% higher than placebo were fatigue, peripheral edema, hypertension, abdominal pain, decreased appetite, proteinuria, nausea, and ascites. The most common laboratory abnormalities at a rate of ≥30% and a ≥2% higher difference in incidence between arms were thrombocytopenia, hypoalbuminemia, and hyponatremia.
No clinically meaningful changes in the exposure of either Cyramza or its concomitant drugs in the approved combinations, including paclitaxel, docetaxel, irinotecan (or its active metabolite, SN-38), and erlotinib were observed in patients with solid tumors.
Hemorrhage : Cyramza increases the risk of hemorrhage and gastrointestinal hemorrhage, including severe and fatal events. Permanently discontinue Cyramza in patients who experience severe bleeding. Gastrointestinal Perforations : Cyramza increases the risk of gastrointestinal perforation, which can be fatal. Permanently discontinue Cyramza in patients who experience a gastrointestinal perforation. Impaired Wound Healing : Withhold Cyramza for 28 days prior to elective surgery. Do not administer Cyramza for at least 2 weeks following a major surgical procedure and until adequate wound healing. The safety of resumption of Cyramza after resolution of wound healing complications has not been established. Arterial Thromboembolic Events (ATEs) : Serious and sometimes fatal ATEs can occur with Cyramza. Permanently discontinue Cyramza in patients who experience an ATE. Hypertension : Monitor blood pressure and treat hypertension. Withhold Cyramza for severe hypertension. Permanently discontinue Cyramza for hypertension that cannot be controlled with antihypertensive therapy and for hypertensive crisis or hypertensive encephalopathy. Infusion-Related Reactions (IRR) : Monitor for signs and symptoms during infusion. Reduce the infusion rate for Grade 1 or 2 IRR and permanently discontinue for Grade 3 or 4 IRR. Worsening of Pre-existing Hepatic Impairment : New onset or worsening encephalopathy, ascites or hepatorenal syndrome can occur in patients with Child-Pugh B or C cirrhosis. Posterior Reversible Encephalopathy Syndrome : Permanently discontinue Cyramza. Proteinuria Including Nephrotic Syndrome : Monitor for proteinuria. Withhold Cyramza for urine protein levels greater than or equal to 2 g per 24 hours. Permanently discontinue Cyramza for urine protein levels greater than 3 g per 24 hours or nephrotic syndrome. Thyroid Dysfunction : Monitor thyroid function during treatment. Embryo-Fetal Toxicity : Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.